TY - JOUR
T1 - Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer
AU - Kilic, Ergin
AU - Schild, Steven E.
AU - Thorns, Christoph
AU - Bajrovic, Amira
AU - Rades, Dirk
N1 - Publisher Copyright:
© 2014, International Institute of Anticancer Research. All rights reserved.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Background/Aim: To present long-term results regarding the role of vascular endothelial growth factor (VEGF) and its receptor-1 (VEGFR-1) for esophageal cancer. Patients and Methods: In 68 esophageal cancer patients, VEGF, VEGFR-1 plus ten other factors were analyzed for locoregional control (LRC), metastases-free survival (MFS) and survival up to 10 years. Results: On multivariate analysis, improved LRC was associated with hemoglobin during radiotherapy ≥12 g/dl (p=0.001). VEGF-negativity showed a trend for better LRC on univariate analysis. On multivariate analysis, better MFS was associated with hemoglobin ≥12 g/dl (p=0.012), better performance status (p=0.009) and lower tumor stage (p=0.032). On multivariate analysis, improved survival was associated with hemoglobin ≥12 g/dl (p<0.001) and better performance status (p=0.005). Trends for improved survival were observed for VEGF-negativity and VEGFR-1-negativity on univariate analysis. Conclusion: VEGF showed a trend towards worse LRC and survival, VEGFR-1 towards worse survival. Outcomes were associated with hemoglobin, performance status and tumor stage.
AB - Background/Aim: To present long-term results regarding the role of vascular endothelial growth factor (VEGF) and its receptor-1 (VEGFR-1) for esophageal cancer. Patients and Methods: In 68 esophageal cancer patients, VEGF, VEGFR-1 plus ten other factors were analyzed for locoregional control (LRC), metastases-free survival (MFS) and survival up to 10 years. Results: On multivariate analysis, improved LRC was associated with hemoglobin during radiotherapy ≥12 g/dl (p=0.001). VEGF-negativity showed a trend for better LRC on univariate analysis. On multivariate analysis, better MFS was associated with hemoglobin ≥12 g/dl (p=0.012), better performance status (p=0.009) and lower tumor stage (p=0.032). On multivariate analysis, improved survival was associated with hemoglobin ≥12 g/dl (p<0.001) and better performance status (p=0.005). Trends for improved survival were observed for VEGF-negativity and VEGFR-1-negativity on univariate analysis. Conclusion: VEGF showed a trend towards worse LRC and survival, VEGFR-1 towards worse survival. Outcomes were associated with hemoglobin, performance status and tumor stage.
UR - http://www.scopus.com/inward/record.url?scp=84908689088&partnerID=8YFLogxK
M3 - Journal articles
C2 - 25202119
AN - SCOPUS:84908689088
SN - 0250-7005
VL - 34
SP - 5221
EP - 5226
JO - Anticancer Research
JF - Anticancer Research
IS - 9
ER -
